Literature DB >> 19428863

CpG-ODN combined with Neospora caninum lysate, but not with excreted-secreted antigen, enhances protection against infection in mice.

Dâmaso P Ribeiro1, Marina M P Freitas, Mariana R D Cardoso, Ana C A M Pajuaba, Neide M Silva, Tiago W P Mineo, João S Silva, José R Mineo, Deise A O Silva.   

Abstract

CpG oligodeoxynucleotides (ODN) have shown to be potent immunoadjuvants for several pathogens, but there is limited information concerning their use in immunization protocols against neosporosis. This study aimed to evaluate the potential of CpG-ODN combined with Neospora lysate antigen (NLA) or excreted-secreted antigen (NcESA) to induce protective immune response against Neospora caninum infection in mice. C57BL/6 mice were vaccinated subcutaneously three times at 2-week intervals with NLA, NLA+CpG, NcESA, NcESA+CpG, CpG (adjuvant control) or PBS (infection control). Serological assays showed an increased specific IgG2a response in animals immunized with either antigen plus adjuvant and elevated levels of the IgG1 isotype in those vaccinated with antigens alone. Splenocyte proliferative responses upon antigen stimulation were higher in groups immunized with NLA or NcESA combined with CpG, showing increased IL-12 levels. Also, mice vaccinated with NcESA or NcESA+CpG demonstrated higher IFN-gamma levels and IFN-gamma/IL-10 ratio. After lethal challenge, mice immunized with NLA+CpG or NLA had lower morbidity score and body weight changes in comparison to other groups, and animals did not succumb during acute infection. In contrast, NcESA+CpG or NcESA groups exhibited the highest morbidity scores, body weight impairment and mortality rates, associated with greatest brain parasite burden and inflammation. In conclusion, CpG-ODN was able to induce a Th1-type humoral immune response with predominant IgG2a levels for either NLA or NcESA, but resulting in an effective Th1-driven cellular immune response and total protection only when combined with NLA. Vaccination with NcESA alone or combined with CpG resulted in a strong cellular immune response associated with high levels of IFN-gamma and inflammation, rendering mice more susceptible to parasite challenge.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19428863     DOI: 10.1016/j.vaccine.2009.02.028

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  13 in total

1.  Protective effect of intranasal immunization with Neospora caninum membrane antigens against murine neosporosis established through the gastrointestinal tract.

Authors:  Pedro Ferreirinha; Joana Dias; Alexandra Correia; Begoña Pérez-Cabezas; Carlos Santos; Luzia Teixeira; Adília Ribeiro; António Rocha; Manuel Vilanova
Journal:  Immunology       Date:  2014-02       Impact factor: 7.397

2.  Protection against lethal Neospora caninum infection in mice induced by heterologous vaccination with a mic1 mic3 knockout Toxoplasma gondii strain.

Authors:  Diana Marcela Penarete-Vargas; Marie Noelle Mévélec; Sarah Dion; Edouard Sèche; Isabelle Dimier-Poisson; Thierry Fandeur
Journal:  Infect Immun       Date:  2009-12-07       Impact factor: 3.441

3.  Comparative Analysis of Antigiardial Potential of Heat Inactivated and Probiotic Protein of Probiotic Lactobacillus rhamnosus GG in Murine Giardiasis.

Authors:  Geeta Shukla; Shweta Kamboj; Bhawna Sharma
Journal:  Probiotics Antimicrob Proteins       Date:  2020-03       Impact factor: 4.609

Review 4.  Vaccines against a Major Cause of Abortion in Cattle, Neospora caninum Infection.

Authors:  Thierry Monney; Karim Debache; Andrew Hemphill
Journal:  Animals (Basel)       Date:  2011-09-08       Impact factor: 2.752

5.  Use of a Th1 Stimulator Adjuvant for Vaccination against Neospora caninum Infection in the Pregnant Mouse Model.

Authors:  Thierry Monney; Denis Grandgirard; Stephen L Leib; Andrew Hemphill
Journal:  Pathogens       Date:  2013-03-27

6.  Dectin-1 Compromises Innate Responses and Host Resistance against Neospora caninum Infection.

Authors:  Murilo Vieira da Silva; Flávia Batista Ferreira França; Caroline Martins Mota; Arlindo Gomes de Macedo Júnior; Eliézer Lucas Pires Ramos; Fernanda Maria Santiago; José Roberto Mineo; Tiago Wilson Patriarca Mineo
Journal:  Front Immunol       Date:  2017-03-07       Impact factor: 7.561

7.  Interplay Between Reactive Oxygen Species and the Inflammasome Are Crucial for Restriction of Neospora caninum Replication.

Authors:  Caroline M Mota; Djalma de S Lima-Junior; Flávia Batista Ferreira França; Jhoan David Aguillón Torres; Patrício da Silva Cardoso Barros; Fernanda Maria Santiago; Joāo Santana Silva; José Roberto Mineo; Dario S Zamboni; Tiago W P Mineo
Journal:  Front Cell Infect Microbiol       Date:  2020-05-25       Impact factor: 5.293

8.  Adjuvant and immunostimulatory effects of a D-galactose-binding lectin from Synadenium carinatum latex (ScLL) in the mouse model of vaccination against neosporosis.

Authors:  Mariana R D Cardoso; Caroline M Mota; Dâmaso P Ribeiro; Pablo G Noleto; William B F Andrade; Maria A Souza; Neide M Silva; Tiago W P Mineo; José R Mineo; Deise A O Silva
Journal:  Vet Res       Date:  2012-10-29       Impact factor: 3.683

9.  Evaluation of colostrum as an alternative biological sample for the diagnosis of human congenital toxoplasmosis.

Authors:  Ana Carolina de Morais Oliveira; Hellen Dayane Silva Borges; Fernando Reis Carvalho; Arlindo Gomes de Macêdo; Caroline Martins Mota; Angela Maria de Morais Oliveira; Fernanda Maria Santiago; Cristina Guimarães Arantes Araújo; Deise Aparecida de Oliveira Silva; Tiago Wilson Patriarca Mineo; Vânia Olivetti Steffen Abdallah; José Roberto Mineo
Journal:  BMC Infect Dis       Date:  2015-11-14       Impact factor: 3.090

10.  Neospora caninum Activates p38 MAPK as an Evasion Mechanism against Innate Immunity.

Authors:  Caroline M Mota; Ana C M Oliveira; Marcela Davoli-Ferreira; Murilo V Silva; Fernanda M Santiago; Santhosh M Nadipuram; Ajay A Vashisht; James A Wohlschlegel; Peter J Bradley; João S Silva; José R Mineo; Tiago W P Mineo
Journal:  Front Microbiol       Date:  2016-09-13       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.